Pricing pressure in the US, the world's largest single country drug market, is showing signs of easing. Analysts expect the pricing pressure to normalise in a year or so reverting to earlier levels of low to mid-single digit. This is primarily because the companies
have off late focussed on rationalising product portfolios as well manufacturing facilities and have exited products with thin margins.
The US market has seen price erosion levels of 5-6 per cent. However, with faster drug approvals and higher rate of launches coupled with consolidation in the wholesale and distribution network, the price erosion got worse in the last few years, rising to high single digit to low teens.
Several Indian pharma majors have already indicated in their earnings calls that they expect pricing pressure to stabilise over the coming months. The largest generic drug manufacturer in the US, Teva Pharmaceuticals, plans to exit 80 per cent of their generic portfolio in response to pricing pressure and has closed more than 10 manufacturing facilities so far.
In a recent note, ICRA said over the last 12-15 months, companies
had been exiting several products where pricing was untenable. For example, Dr Reddy's Laboratories has sold two of its manufacturing facilities - one in India and another in the US - to streamline its manufacturing operations and optimise the cost structure. It basically tried to get out of the commoditised antibiotic portfolio.
These initiatives are likely to reduce competitive pressures enabling normalisation of prices, felt Gaurav Jain, vice-president and co-head corporate ratings, ICRA.
Companies, however, are being cautiously optimistic. A Cipla spokesperson said: "It's difficult to say at this point whether the pricing environment in the US has completely stabilised, and how this will play out in the second half of the quarter, but there is certainly more optimism now."
He said with no products getting added, Cipla's business-to-business (B2B) was experiencing a natural decline by design. A relatively late entrant in the US market, Cipla is focussing on complex generics in that market. "Our effort to improve our product mix with more emphasis on limited competition assets has already started to deliver significant margin improvement and revenue growth," the spokesperson said.
Lupin Chief Executive Officer Vinita Gupta had indicated in the Q2 earnings call: "The US market is gone through a lot of pressure over the last couple of years, but we are starting to see some level of stabilization and moderation in price erosion setting in."
She added: "In the last year or so, we have seen companies
such as Mylan and Teva get out of multiple products in their portfolio presumably because they had reached a threshold below which it was not feasible for them to continue to manufacture the product. So, we are seeing this supply disruption more and more which is a very healthy sign for the industry. We benefited from some of that in Q2 and we expect to continue to see this trend in the next couple of quarters."
Meanwhile, drug makers are consolidating manufacturing facilities and rationalising their product portfolio in the US as they battle price erosion and weak profits.
Sun Pharma, country's largest drug maker by sales, is closing down its manufacturing site at Cranbury in New Jersey, and consolidating operations at its Ohm facility in the same state. It has more than 40 manufacturing plants globally, including five in the US.
“Sun Pharma is consolidating its manufacturing operations at New Brunswick and Cranbury into one location, New Brunswick. The restructuring is aimed at optimising our manufacturing operations and improving cost efficiencies in the increasingly competitive US market," the company said in an emailed response.
"Going forward we could see more brand and plant divestments and investments in automation and technology to reduce costs and improve efficiencies," said Sujay Shetty, (lead - health industry practice), PwC.
Heightened competitive intensity has also led the pharmaceutical companies to prune their portfolios and focus on selective high margin and complex products.
"Between October to September in FY18, companies have withdrawn 606 approved abbreviated new drug applications, as compared to 214 and 248 withdrawals in FY17 and FY16, respectively," ICRA said in a note.